← SynDRA
NERATINIB
SynDRA canonical compound SYN0005562 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | EGFR | ERBB2 | ERBB4 | KDR |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
| Indication | breast cancer |
|---|
| Disease area | oncology |
|---|
All known targets
- ERBB2
- EGFR
- ERBB4
- KDR
- ABL1
- SIK1
- RPS6KA1
- PTK2B
- PTK2
- PRKD3
- PRKD2
- PRKD1
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- ERBB2 INHIBITOR
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- ERBB4 INHIBITOR
- Receptor protein-tyrosine kinase erbB-4 inhibitor
- KDR INHIBITOR
- ERBB2 ANTAGONIST
- EGFR ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- GHSR
- PDE4D
- IGF1R
- HTR2A
- DRD2
- HRH2
- DLK1
- SLC29A1
- PAICS
- OPRD1
- NTRK3
- PGRMC1
- PFKP
- OLA1
- PDXK
- OPA1
- PDPK1
- PDGFRB
- PAK3
- OPRM1
- PDGFRA
- OXSR1
- PHKG1
- PASK
- PAK5
- PAK4
- PDE3A
- PI4KB
- PHKG2
- PIK3C2B
- PRKAA2
- PRKAA1
- PLK4
- PLK3
- PLK2
- PLK1
- PKN2
- PKN1
- PKMYT1
- PIP5K1C
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- HLAB
- IFNB1
- IFNG
- KSYK
- NSD2
- TP53
Drug classes
- Kinase Inhibitors
- Kinase Inhibitor
- P-Glycoprotein Inhibitors
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- NERLYNX
- Nerlynx
- neratinib maleate
- HKI-272
- nerlynx
- CDP-820
- WAY-179272
- Neratinib (ERBB2 inhibitor)
- NERATINIB MALEATE
- UNII-9RM7XY23ZS
- 9RM7XY23ZS
- Neratinib maleate [MI]
- hki-272 maleate
- Nerlynx (TN)
- SCHEMBL2180998
- MolPort-044-561-003
- AKOS030524209
- DS-19892
- HKI 272
- Neratinib (HKI-272)
- PB 272
- JJH94R3PWB
- CHEMBL180022
- 698387-09-6 (free base)
- HKI272
- Neratinib [USAN]
- Neratinib(HKI-272)
- Neratinib [USAN:INN]
- UNII-JJH94R3PWB
- Neratinib- Bio-X
- NERATINIB [INN]
- NERATINIB [MI]
- Neratinib (USAN/INN)
- Neratinib - HKI-272
- NERATINIB [MART.]
- NERATINIB [WHO-DD]
- SCHEMBL571762
- SCHEMBL571763
Reported adverse events
- Epistaxis
- Fatigue
- Hepatotoxicity
- Muscle spasms
- Nail disorder
- Rash
- Weight decreased
- Decreased appetite
- Abdominal distension
- Alanine aminotransferase increased
- Dehydration
- Urinary tract infection
Look up NERATINIB in the interactive SynDRA portal →